Promoter holding
64.27%
VP
Vizyon Pharmaceuticals Private Limited - Due diligence report
A 360° intelligence report on Vizyon Pharmaceuticals: trust score, financial health, credit view, compliance, directors, growth and distress…
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Vizyon Pharmaceuticals — 360° Intelligence Report
Generated from MCA filings & public records90/100
Trust Score
Low Risk
Vizyon Pharmaceuticals is assessed as Low Risk with a Trust Score of 90/100. Vizyon Pharmaceuticals is an active private limited indian non-government company incorporated in 2017, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.
Report generated on 17 Aug 2026 from the latest processed filings. Vizyon Pharmaceuticals Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreLow Risk
90/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
100/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
80/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
90/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
- Liabilities ≈ 38% EBITDA - stretched.
- Open charges exceed net worth - secured lenders rank ahead.
- Profitable - internal accruals available.
Charges position: 1 open (25.00 Lakh) · 0 satisfied (-).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Others | 1 | 48.0 cr |
Compliance Score: 100/100 Low Risk
- Company status is Active as per MCA.
- Annual filings current (balance sheet Mar 2025).
- 1 active GST registration(s).
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| SANDIP PRAKASHRAO KUKSE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| NEELIMA KUKSE | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 2 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
06
Ownership & Group Intelligence
As per FY 2023 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-
Promoters hold a dominant controlling stake - exact percentages are part of the full report.
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 90
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Profit expanded 2.1x year-on-year.
Net margin improved to 24%.
Operating for 9 years.
Active GST registration(s).
Distress signals & risk flags
1 open charge(s) registered - assets are encumbered.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence94/100
Favourable indicators
Suitability as a supplier / customer counterparty.
- Statutory record is clean.
- No distress signals on file.
- Financial filings available for verification.
Banker assessment67/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- 1 open charge(s) of 25.00 Lakh already registered.
- Compliance record supports lending.
Investor view84/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 10 events30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
26 Mar 2025
Charge created
Others - 25.00 Lakh
15 Oct 2018
Director ceased
SANDIP PRAKASHRAO KUKSE
Director ceased
NEELIMA KUKSE
03 Jul 2017
Director appointed
SANDIP PRAKASHRAO KUKSE (Director)
Director appointed
NEELIMA KUKSE (Director)
Director ceased
DEVIDAS SHRIPATRAO KUKSE
Director ceased
MANISH PRAKASHRAO KUKSE
22 Mar 2017
Incorporated
Registered with Roc Mumbai
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
| Company | CIN | Location |
|---|---|---|
| Seoul Metal India Private Limited | U31909UP2019PTC118281 | Noida, Uttar Pradesh, India |
| Aysun Personal Care Private Limited | U24297PB2016PTC054996 | Zirakpur, Punjab, India |
| Sri Enterprises Private Limited | U52609MH2020PTC336299 | Mulund East, Mumbai, Maharashtra, India |
| Calcutta Glass & Glass Pvt Ltd | U26109WB2006PTC109169 | Kolkata, West Bengal, India |
| Hacer Rail Technologies Private Limited | U70102DL2013PTC254041 | New Delhi, Delhi, India |
| Diya Omnia Private Limited | U45400TN2010PTC077583 | Chennai, Tamil Nadu, India |
| Dr. Brita International Private Limited | U33115DL2016PTC302483 | Delhi, Delhi, India |
| Infusion Green Solutions Private Limited | U51909UP2021PTC155789 | Shahpur Bamheta, Uttar Pradesh, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Vizyon Pharmaceuticals before audits and certifications: compliance score 100/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Vizyon Pharmaceuticals: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Vizyon Pharmaceuticals - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Favourable indicators. Trust score 90/100, distress signals and MSME payment-delay disclosures - know whether Vizyon Pharmaceuticals pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Vizyon Pharmaceuticals - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Vizyon Pharmaceuticals an active company?
Vizyon Pharmaceuticals has MCA status “Active” with a compliance score of 100/100 (Low Risk).
Is Vizyon Pharmaceuticals financially healthy?
Vizyon Pharmaceuticals has a Financial Health Score of 80/100 (Low Risk) based on its filed financial statements.
Should I do business with Vizyon Pharmaceuticals?
Its overall Trust Score is 90/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Vizyon Pharmaceuticals?
Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.
Does Vizyon Pharmaceuticals have loans or charges against its assets?
1 open charge(s) are registered against its assets.
Is Vizyon Pharmaceuticals up to date with its ROC filings?
Annual filings current (balance sheet Mar 2025). Overall compliance score: 100/100 (Low Risk).
Is it risky to lend to Vizyon Pharmaceuticals?
Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
